Notably, about 30% of all cancers have an activating mutation in Ras and the vast majority (up to 95%) of pancreatic cancer patients harbor a mutation in K-Ras.35, 36, 37 Unfortunately, thus far, no effective inhibitor of the K-Ras oncoprotein has reached the clinic. This evidence concerns the gene KRAS and pancreatic neoplasm.